| abstract |
The present invention provides a novel pneumococcal vaccine and vaccination of a subject against pneumococcal infection, particularly an immunocompromised subject, using the novel pneumococcal vaccine. A pneumococcal vaccine comprising at least one conjugated capsular saccharide pneumococcal antigen and at least one TLR-9 agonist as an adjuvant. Furthermore, the pneumococcal vaccine wherein one TLR-9 agonist comprises any of CpG oligonucleotides, preferably CpG oligonucleotides. [Selection] Figure 1 |